imatinib mesylate has been researched along with Carcinoma, Ductal, Breast in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arun, BK; Booser, DJ; Cristofanilli, M; Francis, D; Green, MC; Hortobagyi, GN; Islam, R; Krishnamurthy, S; Lee, BN; Lopez, A; Morandi, P; Pusztai, L; Reuben, JM; Valero, V | 1 |
| Cao, Y; Dewhirst, MW; Han, S; Hara, MR; Oliver, T; Shenoy, SK; Zhao, YL | 1 |
| Chow, LW; Loo, WT; Toi, M; Yip, AY | 1 |
2 trial(s) available for imatinib mesylate and Carcinoma, Ductal, Breast
| Article | Year |
|---|---|
Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlations.
Topics: Adult; Antineoplastic Agents; Benzamides; Breast Neoplasms; Breast Neoplasms, Male; Carcinoma, Ductal, Breast; Female; Humans; Imatinib Mesylate; Immunologic Factors; Male; Middle Aged; Neoplasm Metastasis; Piperazines; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta | 2008 |
Evaluation of neoadjuvant inhibition of aromatase activity and signal transduction in breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Benzamides; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Drug Evaluation; Female; Humans; Imatinib Mesylate; Letrozole; Middle Aged; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Nitriles; Pilot Projects; Piperazines; Postmenopause; Pyrimidines; Signal Transduction; Triazoles | 2008 |
1 other study(ies) available for imatinib mesylate and Carcinoma, Ductal, Breast
| Article | Year |
|---|---|
β-arrestin1 mediates metastatic growth of breast cancer cells by facilitating HIF-1-dependent VEGF expression.
Topics: Active Transport, Cell Nucleus; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzamides; Breast Neoplasms; Carcinoma, Ductal, Breast; Cell Line, Tumor; Female; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Imatinib Mesylate; Mice; Mice, Nude; Neoplasm Metastasis; Piperazines; Protein Stability; Pyrimidines; Thalidomide; Transcription, Genetic; Vascular Endothelial Growth Factor A | 2012 |